SCHEMBL5225091

SCHEMBL5225091

COc1ccc(NC(=O)c2cc(NS(=O)(=O)C(F)(F)F)ccc2NC(=O)c2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F10 P00742 5/20 0.61
NR1H4 Q96RI1 5/20 0.57
TRPV1 Q8NER1 3/20 0.52
TP53 P04637 3/20 0.52
RXFP1 Q9HBX9 1/20 0.52
PPARG P37231 2/20 0.51
PPARA Q07869 1/20 0.51
PPARD Q03181 1/20 0.50
GPBAR1 Q8TDU6 1/20 0.50
EPHX2 P34913 1/20 0.49
MAPT P10636 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ALOX15 P16050 1/20 0.49
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5225715 0.89 F10 (0.76) F10NR1H4TRPV1TP53RXFP1
SCHEMBL5225151 0.86 F10 (0.61) F10NR1H4TRPV1TP53RXFP1
SCHEMBL5226610 0.85 NR1H4 (0.60) F10NR1H4TRPV1TP53PPARG
SCHEMBL5222102 0.82 NR1H4 (0.64) F10NR1H4TP53PPARGPPARA
SCHEMBL5225486 0.81 NR1H4 (0.63) F10NR1H4TRPV1TP53RXFP1
SCHEMBL5223117 0.81 F10 (0.64) F10NR1H4TRPV1TP53RXFP1
SCHEMBL5228531 0.80 MEN1 (0.65) F10NR1H4TP53MAPTSMN1; SMN2
SCHEMBL5224050 0.79 NR1H4 (0.60) F10NR1H4TRPV1TP53RXFP1
SCHEMBL5223218 0.79 NR1H4 (0.73) F10NR1H4TP53RXFP1PPARG
SCHEMBL5226416 0.78 NR1H4 (0.59) F10NR1H4TRPV1TP53RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1014962-A4 ANTITHROMBOTIC AGENTS LILLY CO ELI (US) 2007-06-27 EP disclosed
US-6605626-B2 Benzamide inhibitors of factor Xa ELI LILLY AND COMPANY 2003-08-12 US disclosed
US-20020120007-A1 Benzamide inhibitors of factor Xa BEIGHT DOUGLAS WADE (US) 2002-08-29 US disclosed
US-6313122-B1 AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS ELI LILLY AND COMPANY 2001-11-06 US disclosed
EP-1014962-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 2000-07-05 EP disclosed
WO-1999000121-A1 ANTITHROMBOTIC AGENTS ELI LILLY AND COMPANY (US) 1999-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120007-A1 Benzamide inhibitors of factor Xa TFPI, F11, F12 F10 12/4885NR1H4 2304/4885TRPV1 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.